Figure 4: VISTA: TTP (a) and OS (b) for patients receiving VMP according to presence or absence of adverse cytogenetic features (San Miguel et al, 2008a). Reprinted with permission from San Miguel et al, 2008. Copyright © 2008 Massachusetts Medical Society. All rights reserved.